RedHill Biopharma (RDHL) Cash & Equivalents (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Cash & Equivalents data on file, last reported at $4.0 million in Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 13.99% year-over-year to $4.0 million in Q4 2025; TTM through Dec 2025 was $4.0 million, a 13.99% decrease from a year earlier, with the FY2025 full-year figure at $4.6 million, down 17.09% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $4.0 million, down from $4.6 million in the prior quarter.
• Over the last five years, Cash & Equivalents for RDHL reached as high as $76.0 million in Q1 2021 and fell as low as $4.0 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $27.0 million across 5 years, with a median of $20.0 million in 2022.
• Across the five-year window, Cash & Equivalents soared 78.53% in 2021 and sank 72.11% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $29.5 million in 2021, then slumped by 32.25% to $20.0 million in 2022, then sank by 72.11% to $5.6 million in 2023, then decreased by 17.09% to $4.6 million in 2024, then fell by 13.99% to $4.0 million in 2025.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $4.0 million in Q4 2025, $4.6 million in Q2 2025, and $4.6 million in Q4 2024.